Islam, R., Briscoe, C., Bower, J., Cape, S., Arnold, M., Hayes, R., Warren, M., Karnik, S., Stouffer, B., Xiao, Y. Q., van der Strate, B., Sikkema, D., Fang, X., Tudoroniu, A., Tayyem, R., Brant, A., Spriggs, F., Barry, C., Khan, M., Keyhani, A., Zimmer, J., Caturla, M. C., Couerbe, P., Khadang, A., Bourdage, J., Datin, J., Zemo, J., Hughes, N., Fatmi, S., Sheldon, C., Fountain, S., Satterwhite, C., Colletti, K., Vija, J., Yu, M., Stamatopoulos, J., Lin, J., Wilfahrt, J., Dinan, A., Ohorodnik, S., Hulse, J., Patel, V., Garofolo, W., Savoie, N., Brown, M., Papac, D., Buonarati, M., Hristopoulos, G., Beaver, C., Boudreau, N., Williard, C., Liu, Y., Ray, G., Warrino, D., Xu, A., Green, R., Hayward-Sewell, J., Marcelletti, J., Sanchez, C., Kennedy, M., Charles, J. S., Bouhajib, M., Nehls, C., Tabler, E., Tu, J., Joyce, P., Iordachescu, A., DuBey, I., Lindsay, J., Yamashita, J., & Wells, E. (2018). 11th GCC Closed Forum: cumulative stability; matrix stability; immunogenicity assays; laboratory manuals; biosimilars; chiral methods; hybrid LBA/LCMS assays; fit-for-purpose validation; China Food and Drug Administration bioanalytical method validation. Bioanalysis, 10, 433–444. http://access.bl.uk/ark:/81055/vdc_100120178015.0x000009